Abbott Laboratories banner

Abbott Laboratories
F:ABL

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
F:ABL
Watchlist
Price: 83.02 EUR 1.54%
Market Cap: €144.4B

EV/EBITDA

14.5
Current
27%
Cheaper
vs 3-y average of 19.7

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
14.5
=
Enterprise Value
€166.8B
/
EBITDA
$11.6B

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
14.5
=
Enterprise Value
€166.8B
/
EBITDA
$11.6B

Valuation Scenarios

Abbott Laboratories is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (19.7), the stock would be worth €113.04 (36% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-11%
Maximum Upside
+36%
Average Upside
14%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 14.5 €83.02
0%
3-Year Average 19.7 €113.04
+36%
5-Year Average 19.1 €109.39
+32%
Industry Average 12.9 €73.8
-11%
Country Average 14.4 €82.22
-1%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
€166.8B
/
Apr 2026
$11.6B
=
14.5
Current
€166.8B
/
Dec 2026
$13.2B
=
12.6
Forward
€166.8B
/
Dec 2027
$14.5B
=
11.5
Forward
€166.8B
/
Dec 2028
$15.6B
=
10.7
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
US
Abbott Laboratories
F:ABL
166.7B EUR 14.5 26.6
US
Intuitive Surgical Inc
NASDAQ:ISRG
165.3B USD 43.9 57.9
US
Stryker Corp
NYSE:SYK
129.4B USD 20.4 39.9
IE
Medtronic PLC
NYSE:MDT
109.1B USD 13.1 23.6
US
Boston Scientific Corp
NYSE:BSX
90.4B USD 18.6 31.2
DE
Siemens Healthineers AG
XETRA:SHL
43.2B EUR 11.5 20.7
US
Edwards Lifesciences Corp
NYSE:EW
47.3B USD 24 44.1
US
IDEXX Laboratories Inc
NASDAQ:IDXX
46.5B USD 31 43.9
US
Becton Dickinson and Co
NYSE:BDX
45.2B USD 10.1 25.7
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
33.8B USD 11.6 16.2
US
Resmed Inc
NYSE:RMD
32.9B USD 15.6 22.2

Market Distribution

In line with most companies in the United States of America
Percentile
44th
Based on 9 875 companies
44th percentile
12.8
Low
0 — 10
Typical Range
10 — 21.5
High
21.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 10
Median 14.4
70th Percentile 21.5
Max 1 767 274.1

Abbott Laboratories
Glance View

Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.

ABL Intrinsic Value
99.46 EUR
Undervaluation 17%
Intrinsic Value
Price €83.02
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett